Proshrs Ultra Nq Bio (BIB) 38.91 $BIB Look for Shares of

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Proshrs Ultra Nq Bio (BIB) 38.91 $BIB

Look for Shares of ProShares Ultra Nasdaq Biotechnology ETF to Potentially Pullback after Yesterday's 2.99% Rise
Comtex SmarTrend(R) - Tue May 31, 4:52PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $45.54 to a high of $46.80. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $45.15 on volume of 628,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

Watch for ProShares Ultra Nasdaq Biotechnology ETF to Potentially Pullback After Gaining 1.72% Yesterday
Comtex SmarTrend(R) - Fri May 27, 3:22PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $44.03 to a high of $45.14. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $45.10 on volume of 257,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

After Yesterday's Rally of 1.14% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 23, 3:18PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $41.26 to a high of $42.66. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $41.69 on volume of 446,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

ProShares Ultra Nasdaq Biotechnology ETF Rises 1.85% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Apr 18, 4:17PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $46.55 to a high of $49.05. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $47.93 on volume of 521,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

Watch for ProShares Ultra Nasdaq Biotechnology ETF to Potentially Pullback After Gaining 4.09% Yesterday
Comtex SmarTrend(R) - Mon Apr 04, 3:45PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $43.33 to a high of $45.17. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $43.44 on volume of 796,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

New Strong Buy Stocks for April 4th
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 9:14AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
ALGN: 80.42 (+1.08), BIB: 38.91 (+0.60), CNS: 40.03 (-0.04), AKG: 4.10 (+0.02), SFR: 29.63 (-0.22)

ProShares Ultra Nasdaq Biotechnology ETF Set to Possibly Pullback After Yesterday's Rally of 5.95%
Comtex SmarTrend(R) - Thu Mar 31, 2:33PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $39.13 to a high of $41.53. Yesterday, the shares gained 6.0%, which took the trading range above the 3-day high of $41.48 on volume of 560,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

ProShares Ultra Nasdaq Biotechnology ETF Has Returned 33.7% Since SmarTrend Recommendation (BIB)
Comtex SmarTrend(R) - Fri Feb 05, 5:44PM CST
SmarTrend identified a Downtrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on January 7th, 2016 at $60.55. In approximately 4 weeks, ProShares Ultra Nasdaq Biotechnology ETF has returned 33.67% as of today's recent price of $40.16.
BIB: 38.91 (+0.60)

Downtrend Call Working As ProShares Ultra Nasdaq Biotechnology ETF Stock Falls 30.1% (BIB)
Comtex SmarTrend(R) - Fri Jan 29, 5:04PM CST
SmarTrend identified a Downtrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on January 7th, 2016 at $60.55. In approximately 3 weeks, ProShares Ultra Nasdaq Biotechnology ETF has returned 30.07% as of today's recent price of $42.34.
BIB: 38.91 (+0.60)

BUYINS.NET: FXR, XIN, PRIM, HIL, MVV, BIB Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Jan 25, 6:25AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of First Trust Industrials/Producer Drbls AlphaDEX Fd (NYSE:FXR), iShares MSCI EAFE Index (CAD-Hedged) (NYSE:XIN), PRIMORIS SERVICES CORPORATION (NASDAQRIM), Hill International Inc (NYSE:HIL), ProShares Ultra MidCap400 (NYSE:MVV), ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
HIL: 4.32 (unch), PRIM: 19.12 (-0.22), MVV: 76.40 (-0.53), BIB: 38.91 (+0.60), XIN: 5.01 (+0.01), FXR: 28.16 (-0.04)

ProShares Ultra Nasdaq Biotechnology ETF Has Returned 18.5% Since SmarTrend Recommendation (BIB)
Comtex SmarTrend(R) - Fri Jan 22, 12:48PM CST
SmarTrend identified a Downtrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on January 7th, 2016 at $60.55. In approximately 2 weeks, ProShares Ultra Nasdaq Biotechnology ETF has returned 18.46% as of today's recent price of $49.37.
BIB: 38.91 (+0.60)

BUYINS.NET: NOG, HTHT, BIB, KKR, HBM, JMP Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Dec 18, 6:51AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Nordic Oil and Gas Ltd (NYSE:NOG), China Lodging Group Ltd (NASDAQ:HTHT), ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB), KKR & Co. L.P. (NYSE:KKR), HudBay Minerals Inc (NYSE:HBM), JMP Group Inc (NYSE:JMP) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
NOG: 4.89 (+0.04), JMP: 5.54 (+0.03), BIB: 38.91 (+0.60), HBM: 5.04 (-0.04), KKR: 13.01 (-0.07), HTHT: 34.60 (+0.33)

BUYINS.NET: DFT, JKL, IYT, BIB, KKR, NOAH Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Dec 02, 8:25PM CST
November 20, 2015
NOAH: 23.49 (+0.01), DFT: 46.15 (-0.02), BIB: 38.91 (+0.60), JKL: 123.04 (-0.59), KKR: 13.01 (-0.07), IYT: 136.38 (-0.88)

SmarTrend Watching for Potential Pullback in Shares of ProShares Ultra Nasdaq Biotechnology ETF After 2.04% Gain
Comtex SmarTrend(R) - Wed Nov 25, 5:25PM CST
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $70.60 to a high of $72.42. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $72.09 on volume of 493,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

BUYINS.NET: NEPT, SBH, AIMC, CVLT, MHH, BIB Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Oct 23, 8:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Neptun SA (NASDAQ:NEPT), Sally Beauty Holdings Inc (NYSE:SBH), Altra Holdings Inc (NASDAQ:AIMC), CommVault Systems Inc (NASDAQ:CVLT), Mastech Holdings Inc (NYSE:MHH), ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
BIB: 38.91 (+0.60), SBH: 28.43 (-0.05), MHH: 6.56 (+0.15), CVLT: 44.93 (-0.85), AIMC: 27.87 (-0.27), NEPT: 1.04 (unch)

ProShares Ultra Nasdaq Biotechnology ETF Set to Possibly Pullback After Yesterday's Rally of 1.04%
Comtex SmarTrend(R) - Mon Oct 19, 4:45PM CDT
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $60.36 to a high of $65.30. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $64.21 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIB: 38.91 (+0.60)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

PARRIS Law Firm Triumphs in Landmark Billing Case Against Edison

Updated Category News Views 258

PARRIS Law Firm Achieves Major Victory in Consumer Lawsuit The PARRIS Law Firm has recently celebrated a significant win for consumers in a landmark lawsuit against Southern California Edison Company. This case, referencing the Wellman v. Southern California Edison Company, has captured media attention, notably from The Daily Journal, showcasing the firm’s commitment to...

Continue Reading
Intercont (Cayman) Limited's Growth: Exploring Recent Financials

Updated Category News Views 112

Intercont (Cayman) Limited Unveils Financial Results Intercont (Cayman) Limited (NASDAQ: NCT), a prominent leader in the global shipping industry, has shared its financial results for the first half of the fiscal year. The company, renowned for its innovative approach to seaborne pulping operations, reported notable advancements in its financial performance, reflecting...

Continue Reading
What to Expect from Quanex Building Products' Earnings Report

Updated Category News Views 107

Understanding the Upcoming Earnings of Quanex Building Products Quanex Building Products (NASDAQ: NX) is gearing up to announce its quarterly earnings. This moment has been highly anticipated by investors eager to gain insights into the company's financial health. While specific dates are typically essential to focus on, the critical takeaway for investors is the...

Continue Reading
ZERO Fresh Start: RAVEN2's New Era Begins Sept 15

Updated Category News Views 18

What's the Big Deal with ZERO? Alright, so here we go, folks—Netmarble's strapping in with their latest server for RAVEN2, and it's called ZERO. Ever heard of fresh starts? ZERO is exactly that. This isn't your usual server shuffle. Lads and ladies who've felt the grind’ll tell you, ZERO's introducing a slew of changes you might want to sit up for. Pre-registration's...

Continue Reading
Innovative Cancer Treatments: CMU and Healthcare System Lead the Way

Updated Category News Views 266

Revolutionizing Cancer Treatment China Medical University (CMU) and Healthcare System are making significant strides in the field of cancer treatment, notably through AI-driven drug discovery and innovative therapies. At a recent healthcare exposition, these organizations showcased their leading-edge advancements, establishing themselves as pioneers in healthcare...

Continue Reading